Federated Hermes’s Unity Biotechnology UBX Stock Holding History

Federated Hermes’s Portfolio UBX Stock Details UBX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-205	Closed	-$562	–	2265
2022 Q4	$562	Sell	205 -69	-25%	-$200	﹤0.01%	2081
2022 Q3	$1K	Sell	274 -90	-25%	-$568	﹤0.01%	2085
2022 Q2	$2K	Buy	364 +16	+5%	+$133	﹤0.01%	1998
2022 Q1	$4K	Buy	+348	New	+$3.9K	﹤0.01%	1986
2020 Q3	–	Sell	-168	Closed	-$15K	–	2349
2020 Q2	$15K	Buy	+168	New	+$12.5K	﹤0.01%	1905

Other funds holding UBX

AVM

Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

Mayo Clinic Rochester, Minnesota $2.9M AUM 14.49% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ECM

ExodusPoint Capital Management New York $12.6B AUM 30.13% 1-Year Est. Return

AWA

Arete Wealth Advisors Chicago, Illinois $1.33B AUM 25.12% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Federated Hermes's UBX Position: Q1 2023 in Review

Federated Hermes sold out of Unity Biotechnology (UBX) in Q1 2023, closing a stake of 205 shares — an estimated $562 sold.

Federated Hermes first reported a position in UBX in Q2 2020 and held it in 5 quarters. The position peaked at $15K in Q2 2020. 46 funds tracked by Wall St. Rank hold UBX as of Q1 2023.

Federated Hermes reported no remaining Unity Biotechnology position as of Q1 2023 after selling out during the quarter.
Federated Hermes sold 205 Unity Biotechnology shares in Q1 2023, an estimated $562.
Federated Hermes first reported a position in Unity Biotechnology in Q2 2020 and held it in 5 quarters.
Federated Hermes's Unity Biotechnology position peaked at $15K in Q2 2020.
46 funds tracked by Wall St. Rank held Unity Biotechnology as of Q1 2023.

Based on Federated Hermes's 13F filing for Q1 2023, filed 8 May 2023.